Lifeloc Technologies earnings release, August 14, 2026

Lifeloc Technologies, Inc (LCTC) · Form 8-K, Item 2.02 · Filed · SEC filing

Lifeloc

Reports Second Quarter 2026 Results

WHEAT

RIDGE, Colo., August 13, 2026 -- Lifeloc Technologies, Inc. (OTCID: LCTC), a global leader in the development and manufacturing of breath alcohol and drug testing devices, has announced financial results for the quarter ended June 30, 2026.

Second

Quarter Financial Highlights

Lifeloc posted quarterly net revenue of $2.445 million in the second quarter of 2026, resulting in a quarterly net loss of $(134) thousand, or $(0.05) per diluted share. These results compare to net revenue of $2.219 million and quarterly net loss of $(394) thousand, or $(0.14) per diluted share in the second quarter of 2025. Revenue for the quarter grew 10% versus the second quarter last year. Six-month net revenues of $4.739 million and a net loss of $(287) thousand, or $(0.10) per diluted share, compared to net revenue of $4.496 million and a net loss of $(686) thousand, or $(0.25) per diluted share, for the same period in 2025.

Total gross margin in the second quarter rose to 45% versus 42% for the same quarter last year. For the first six months of 2026, gross margin was 44% versus 41% for the same period last year, with price increases and a favorable product mix contributing to the higher margins. The research and development investment for the quarter remained high at $560 thousand, primarily for SpinDetect™ analyzer development, resulting in the current period loss.

Alcohol

Detection Products

We believe our core alcohol detection product line-up is strong. The L-series LX9 and LT7 units have features and performance that drive market penetration by meeting previously unaddressable market needs, such as smart phone pairing, wider temperature use ranges and fast customization that incorporates local languages. We expect that sales of our newer L-series devices will be incremental to FC-series devices rather than displacing FC sales. The L-series devices have been certified to meet the requirements of most modern registration standards, such as the latest AS 3547:2019 standards for Breath Alcohol Detectors from SAI Global (formerly Standards Australia International).

Our FC-series devices remain popular with many law enforcement and international organizations. Our Easycal® automated calibration station, the only automated calibration available for portable breath alcohol testers, builds valuable protection around our brand and has contributed to market share gains across the board, especially for our workplace Phoenix® 6.0 BT and EV 30 devices.

SpinDetect™

Analyzer Platform

We believe our most significant long-term opportunity lies at the intersection of the global need for rapid, quantitative drug detection and our proven expertise in portable testing instrumentation. Our SpinDetect™ Centrifugal Drug Analyzer — sometimes referred to as "Lab on a Disk" — is designed to address this need, enabling rapid, on-site, quantitative drug testing for use at roadside, in emergency rooms, forensic labs, and workplace testing sites. We have demonstrated the platform's ability to effectively detect delta-9-THC, cocaine, fentanyl, amphetamine/methamphetamine, morphine, MDMA, and benzodiazepines from oral fluid. We have validated our test results against liquid chromatography-mass spectrometry (LC-MS) — the definitive laboratory standard — using real-world human saliva samples, confirming a limit of detection of approximately 10 ng/ml.

We have completed the design of the SpinDetect™ microfluidic disk, with all analytical chemistry now occurring on the disk after sample introduction. Disk design represented the primary technical challenge throughout the project, requiring specialized outside expertise and multiple design iterations. Disks have been molded and assays loaded for evaluation, with final component and process optimization ongoing. Reader hardware, firmware, drug assays, and reagent handling have been developed in parallel and are substantially complete.

We will be initiating beta testing of the oral-fluid analyzer, focused on delta-9-THC detection using a prototype reader, under a signed beta-testing agreement, and are now targeting a limited commercial launch in Q1 of 2027.

“It is great to see assays performed with all the chemistry occurring on the disk. With our second dispensing robot scheduled for delivery later this month, we are moving closer to production,” commented Dr. Wayne Willkomm, President and CEO. “Oral fluid drug screening will only be the first launching application of this technology platform. We expect subsequent releases to expand to additional drug panels and to samples collected from blood and breath, as well as to other applications, including select non-drug applications such as food pathogen detection.”

Financing

Update

During the quarter, Lifeloc closed on $500,000 of financing, securing a loan from our Chairman of the Board, who also serves as our Chief Financial

Officer. This loan is detailed in our 8-K filing of May 8, 2026, and the key terms are 10.5% interest, adjustable upward based on the prime rate, interest only payments in 2026, followed by monthly payments that will result in the loan being fully paid in 5 years, and no prepayment penalty. The loan is secured by all of our assets. After exploring multiple financing options, the Company determined these terms were more favorable than alternatives available from commercial sources.

About

Lifeloc Technologies

Lifeloc

Technologies, Inc. (OTCID: LCTC) is a trusted U.S. manufacturer of evidential breath alcohol testers and related training and supplies for Workplace, Law Enforcement, Corrections and International customers. Lifeloc stock trades over-the-counter under the symbol LCTC.

We are a fully reporting Company with our SEC filings available on our web site, www.lifeloc.com/investor.

Forward

Looking Statements

Financial statements

Balance Sheet

Condensed Balance Sheets (Unaudited)

ASSETSCURRENT ASSETS:June 30, 2026December 31, 2025
ASSETSCash and cash equivalents908,208746,001
ASSETSAccounts receivable, net826,715772,380
ASSETSInventories, net2,839,5162,633,614
ASSETSFederal and state income taxes receivable55,98155,981
ASSETSPrepaid expenses and other146,90160,825
ASSETSTotal current assets4,777,3214,268,801
PROPERTY, PLANT AND EQUIPMENT:Land317,932317,932
PROPERTY, PLANT AND EQUIPMENT:Building1,928,7951,928,795
PROPERTY, PLANT AND EQUIPMENT:Real-time Alcohol Detection And Recognition equipment and software569,448569,448
PROPERTY, PLANT AND EQUIPMENT:Production equipment, software and space modifications1,366,5391,366,539
PROPERTY, PLANT AND EQUIPMENT:Office equipment, software and space modifications197,686197,686
PROPERTY, PLANT AND EQUIPMENT:Sales and marketing equipment and space modifications230,543225,173
PROPERTY, PLANT AND EQUIPMENT:Research and development equipment, software and space modifications1,247,2011,213,195
PROPERTY, PLANT AND EQUIPMENT:Research and development equipment, software and space modifications not in service19,595
PROPERTY, PLANT AND EQUIPMENT:Less accumulated depreciation-3,670,607-3,538,455
PROPERTY, PLANT AND EQUIPMENT:Total property and equipment, net2,187,5372,299,908
OTHER ASSETS:Patents, net67,22971,039
OTHER ASSETS:Deposits and other46,82046,820
OTHER ASSETS:Total other assets114,049117,859
OTHER ASSETS:Total assets7,078,9076,686,568
CURRENT LIABILITIES:Accounts payable501,118301,627
CURRENT LIABILITIES:Term loans payable, current portion94,77454,850
CURRENT LIABILITIES:Subordinated debentures payable, current portion35,69733,371
CURRENT LIABILITIES:Customer deposits20,33625,694
CURRENT LIABILITIES:Accrued expenses350,141321,112
CURRENT LIABILITIES:Deferred revenue, current portion50,46453,716
CURRENT LIABILITIES:Product warranty reserve46,50046,500
CURRENT LIABILITIES:Total current liabilities1,099,030836,870
CURRENT LIABILITIES:TERM LOAN PAYABLE, net of current portion and debt issuance costs1,030,3641,058,426
CURRENT LIABILITIES:TERM LOAN PAYABLE (Related Party), net of current portion and debt issuance costs460,922
CURRENT LIABILITIES:SUBORDINATED DEBENTURES PAYABLE, net of current portion and debt issuance costs662,901681,343
CURRENT LIABILITIES:DEFERRED REVENUE, net of current portion8,9556,151
CURRENT LIABILITIES:Total liabilities3,262,1722,582,790
STOCKHOLDERS’ EQUITY:Common stock, no par value; 50,000,000 shares authorized, 2,752,616 shares outstanding5,934,3145,934,314
STOCKHOLDERS’ EQUITY:Accumulated deficit-2,117,579-1,830,536
STOCKHOLDERS’ EQUITY:Total stockholders’ equity3,816,7354,103,778
STOCKHOLDERS’ EQUITY:Total liabilities and stockholders’ equity7,078,9076,686,568

Cash Flow

Six months Ended June 30, — Condensed Statements of Cash Flows (Unaudited)

Six months Ended June 30, – 2026Six months Ended June 30, – 2025
Net (loss)-287,043-686,325
Adjustments to reconcile net (loss) to net cash (used in) operating activities-Depreciation and amortization135,962216,419
Adjustments to reconcile net (loss) to net cash (used in) operating activities-Amortization of debt issuance costs12,1035,886
Changes in operating assets and liabilities-Accounts receivable-54,335-33,189
Changes in operating assets and liabilities-Inventories-205,9027,645
Changes in operating assets and liabilities-Federal and state income taxes receivable25,029
Changes in operating assets and liabilities-Prepaid expenses and other-86,076-120,034
Changes in operating assets and liabilities-Accounts payable199,491141,419
Changes in operating assets and liabilities-Customer deposits-5,358-6,186
Changes in operating assets and liabilities-Accrued expenses29,02955,416
Changes in operating assets and liabilities-Deferred revenue-4484,344
Changes in operating assets and liabilities-Net cash (used in) operating activities-262,577-389,576
CASH FLOWS (USED IN) INVESTING ACTIVITIES:Purchases of sales and marketing equipment-5,370-5,462
CASH FLOWS (USED IN) INVESTING ACTIVITIES:Purchases of research and development equipment, software and space modifications-14,411-17,348
CASH FLOWS (USED IN) INVESTING ACTIVITIES:Purchases of research and development equipment, software and space modifications not in service-219,441
CASH FLOWS (USED IN) INVESTING ACTIVITIES:Net cash (used in) investing activities-19,781-242,251
CASH FLOWS PROVIDED BY (USED IN) FINANCING ACTIVITIES:Principal payments made on term loan-28,290-27,469
CASH FLOWS PROVIDED BY (USED IN) FINANCING ACTIVITIES:Proceeds from issuance of subordinated debenture75,000
CASH FLOWS PROVIDED BY (USED IN) FINANCING ACTIVITIES:Proceeds (related party) from issuance of term loan500,000
CASH FLOWS PROVIDED BY (USED IN) FINANCING ACTIVITIES:Principal payments made on subordinated debentures-27,145
CASH FLOWS PROVIDED BY (USED IN) FINANCING ACTIVITIES:Proceeds from issuance of shares from option exercise336,300
CASH FLOWS PROVIDED BY (USED IN) FINANCING ACTIVITIES:Net cash provided from (used in) financing activities444,565383,831
CASH FLOWS PROVIDED BY (USED IN) FINANCING ACTIVITIES:NET INCREASE (DECREASE) IN CASH162,207-247,996
CASH FLOWS PROVIDED BY (USED IN) FINANCING ACTIVITIES:CASH, BEGINNING OF PERIOD746,0011,243,746
CASH FLOWS PROVIDED BY (USED IN) FINANCING ACTIVITIES:CASH, END OF PERIOD908,208995,750
SUPPLEMENTAL INFORMATION:Cash paid for interest59,26444,914
Full release

This... (truncated)ivate Securities Litigation Reform Act of 1995, which involve substantial risks and uncertainties that may cause actual results to differ materially from those indicated by the forward-looking statements.

All forward-looking statements expressed or implied in this press release, including statements about our strategies, performance, expectations about new and existing products, market demand, economic conditions, acceptance of new and existing products, technologies and opportunities, market size and growth, market liquidity for our shares, and return on investments in products and market, are based on information available to us on the date of this document, and we assume no obligation to update such forward-looking statements. Investors are strongly encouraged to review the section titled “Risk Factors” in our SEC filings.

Phoenix® and Easycal® are registered trademarks of Lifeloc Technologies, Inc.

SpinDetect™ is a trademark of Lifeloc Technologies, Inc.

Amy

Evans

Lifeloc Technologies, Inc. http://www.lifeloc.com

(303) 431-9500

LIFELOC TECHNOLOGIES, INC.

Condensed Balance Sheets (Unaudited)

LIFELOC TECHNOLOGIES, INC.

Condensed Statements of Profit (Loss) (Unaudited)

LIFELOC TECHNOLOGIES, INC.

Condensed Statements of Profit (Loss) (Unaudited)

LIFELOC TECHNOLOGIES, INC.

Condensed Statements of Changes in Stockholders’ Equity (Unaudited)

For the Three and Six Months Ended June 30, 2026 and 2025

LIFELOC TECHNOLOGIES, INC.

Condensed Statements of Cash Flows (Unaudited)

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Lifeloc Technologies earnings · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.